Literature DB >> 28692326

Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth.

Gabrielle Dias Salton1, Claudia Cilene Fernandes Correia Laurino2, Nicolás Oliveira Mega3, Andrés Delgado-Cañedo4, Niclas Setterblad5, Maryvonnick Carmagnat6, Ricardo Machado Xavier7, Elizabeth Cirne-Lima8, Guido Lenz9, João Antonio Pêgas Henriques10, Jomar Pereira Laurino11.   

Abstract

BACKGROUND: Eukaryote initiation factor 2 subunit β (eIF2β) plays a crucial role in regulation protein synthesis, which mediates the interaction of eIF2 with mRNA. eIF2β contains evolutionarily conserved polylysine stretches in amino-terminal region and a zinc finger motif in the carboxy-terminus.
METHODS: The gene eIF2β was cloned under tetracycline transcription control and the polylysine stretches were deleted by site-directed mutagenesis (eIF2βΔ3K). The plasmid was transfected into HEK 293 TetR cells. These cells were analyzed for their proliferative and translation capacities as well as cell death rate. Experiments were performed using gene reporter assays, western blotting, flow cytometry, cell sorting, cell proliferation assays and confocal immunofluorescence.
RESULTS: eIF2βΔ3K affected negatively the protein synthesis, cell proliferation and cell survival causing G2 cell cycle arrest and increased cell death, acting in a negative dominant manner against the native protein. Polylysine stretches are also essential for eIF2β translocated from the cytoplasm to the nucleus, accumulating in the nucleolus and eIF2βΔ3K did not make this translocation. DISCUSSION: eIF2β is involved in the protein synthesis process and should act in nuclear processes as well. eIF2βΔ3K reduces cell proliferation and causes cell death. Since translation control is essential for normal cell function and survival, the development of drugs or molecules that inhibit translation has become of great interest in the scenario of proliferative disorders. In conclusion, our results suggest the dominant negative eIF2βΔ3K as a therapeutic strategy for the treatment of proliferative disorders and that eIF2β polylysine stretch domains are promising targets for this.

Entities:  

Keywords:  Cell Proliferation; Cell viability; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factors; Nucleolar organizer region associated proteins; Protein Biosynthesis; Translational Medical Research

Mesh:

Substances:

Year:  2017        PMID: 28692326      PMCID: PMC5653189          DOI: 10.1080/15384047.2017.1345383

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  72 in total

1.  GTP-dependent recognition of the methionine moiety on initiator tRNA by translation factor eIF2.

Authors:  Lee D Kapp; Jon R Lorsch
Journal:  J Mol Biol       Date:  2004-01-23       Impact factor: 5.469

2.  New unstable variants of green fluorescent protein for studies of transient gene expression in bacteria.

Authors:  J B Andersen; C Sternberg; L K Poulsen; S P Bjorn; M Givskov; S Molin
Journal:  Appl Environ Microbiol       Date:  1998-06       Impact factor: 4.792

Review 3.  The cancerous translation apparatus.

Authors:  Craig R Stumpf; Davide Ruggero
Journal:  Curr Opin Genet Dev       Date:  2011-05-03       Impact factor: 5.578

4.  Interaction of eukaryotic translation initiation factor 4G with the nuclear cap-binding complex provides a link between nuclear and cytoplasmic functions of the m(7) guanosine cap.

Authors:  L McKendrick; E Thompson; J Ferreira; S J Morley; J D Lewis
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 5.  Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment.

Authors:  Antonis E Koromilas
Journal:  Biochim Biophys Acta       Date:  2014-12-11

6.  The beta subunit of eukaryotic translation initiation factor 2 binds mRNA through the lysine repeats and a region comprising the C2-C2 motif.

Authors:  J P Laurino; G M Thompson; E Pacheco; B A Castilho
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

7.  Novel cell-based method to detect Shiga toxin 2 from Escherichia coli O157:H7 and inhibitors of toxin activity.

Authors:  Beatriz Quiñones; Shane Massey; Mendel Friedman; Michelle S Swimley; Ken Teter
Journal:  Appl Environ Microbiol       Date:  2009-01-09       Impact factor: 4.792

8.  A nuclear translation-like factor eIF4AIII is recruited to the mRNA during splicing and functions in nonsense-mediated decay.

Authors:  Maria A Ferraiuolo; Chung-Sheng Lee; Lian Wee Ler; Jeanne L Hsu; Mauro Costa-Mattioli; Ming-Juan Luo; Robin Reed; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

9.  Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels.

Authors:  I B Rosenwald; R Kaspar; D Rousseau; L Gehrke; P Leboulch; J J Chen; E V Schmidt; N Sonenberg; I M London
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

10.  eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation.

Authors:  Rita Spilka; Christina Ernst; Helmut Bergler; Johannes Rainer; Susanne Flechsig; Alexander Vogetseder; Eva Lederer; Martin Benesch; Andrea Brunner; Stephan Geley; Andreas Eger; Felix Bachmann; Wolfgang Doppler; Peter Obrist; Johannes Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2014-07-29       Impact factor: 6.730

View more
  1 in total

1.  eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.

Authors:  Ichidai Tanaka; Mitsuo Sato; Toshio Kato; Daiki Goto; Tomohiko Kakumu; Ayako Miyazawa; Naoyuki Yogo; Tetsunari Hase; Masahiro Morise; Yoshitaka Sekido; Luc Girard; John D Minna; Lauren A Byers; John V Heymach; Kevin R Coombes; Masashi Kondo; Yoshinori Hasegawa
Journal:  Cancer Sci       Date:  2018-05-25       Impact factor: 6.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.